All In Biotech

Drug Trial Radar · NCT01482767

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

Last checked: Nov 20, 2026Latest source record: Nov 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

262

Actual

Start

Apr 2012

Primary completion

Apr 2015

Study completion Apr 2015

Sponsor

Sponsor type
NIH
First posted
Dec 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.

Conditions

  • HIV Infections
  • Hepatitis C

Interventions

  • Pegylated-Interferon Alfa 2b (PEG-IFN)Drug

    1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.

  • Ribavirin (RBV)Drug

    800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.

  • Boceprevir (BOC)Drug

    800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)Time frame: 24 weeks after treatment discontinuation

Locations

43 sites in 2 countries. Site status is shown where the registry gives one.

  • Alabama CRS

    Birmingham, Alabama

  • University of Southern California CRS

    Los Angeles, California

  • UCLA CARE Center CRS

    Los Angeles, California

  • Stanford AIDS Clinical Trials Unit CRS

    Palo Alto, California

  • UCSD Antiviral Research Center CRS

    San Diego, California

  • Ucsf Hiv/Aids Crs

    San Francisco, California

  • Harbor-UCLA CRS

    Torrance, California

  • University of Colorado Hospital CRS

    Aurora, Colorado

  • Denver Public Health CRS

    Denver, Colorado

  • Georgetown University CRS (GU CRS)

    Washington D.C., District of Columbia

  • The Ponce de Leon Center CRS

    Atlanta, Georgia

  • Northwestern University CRS

    Chicago, Illinois

  • Rush University CRS

    Chicago, Illinois

  • IHV Baltimore Treatment CRS

    Baltimore, Maryland

  • Johns Hopkins University CRS

    Baltimore, Maryland

  • Massachusetts General Hospital CRS (MGH CRS)

    Boston, Massachusetts

  • Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS

    Boston, Massachusetts

  • Bmc Actg Crs

    Boston, Massachusetts

  • Wayne State Univ. CRS

    Detroit, Michigan

  • Henry Ford Hosp. CRS

    Detroit, Michigan

  • Washington University Therapeutics (WT) CRS

    St Louis, Missouri

  • Cooper Univ. Hosp. CRS

    Camden, New Jersey

  • New Jersey Medical School Clinical Research Center CRS

    Newark, New Jersey

  • Weill Cornell Chelsea CRS

    New York, New York

  • Columbia P&S CRS

    New York, New York

  • Weill Cornell Uptown CRS

    New York, New York

  • University of Rochester Adult HIV Therapeutic Strategies Network CRS

    Rochester, New York

  • Bronx-Lebanon Hosp. Ctr. CRS

    The Bronx, New York

  • Chapel Hill CRS

    Chapel Hill, North Carolina

  • Duke Univ. Med. Ctr. Adult CRS

    Durham, North Carolina

  • Cincinnati Clinical Research Site

    Cincinnati, Ohio

  • Case Clinical Research Site

    Cleveland, Ohio

  • MetroHealth CRS

    Cleveland, Ohio

  • Ohio State University CRS

    Columbus, Ohio

  • Penn Therapeutics, CRS

    Philadelphia, Pennsylvania

  • University of Pittsburgh CRS

    Pittsburgh, Pennsylvania

  • The Miriam Hospital Clinical Research Site (TMH CRS) CRS

    Providence, Rhode Island

  • Vanderbilt Therapeutics (VT) CRS

    Nashville, Tennessee

  • Trinity Health and Wellness Center CRS

    Dallas, Texas

  • Houston AIDS Research Team CRS

    Houston, Texas

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.